View from the U.S.: BIO chief defends industry amid pricing debate
By Nuala Moran
Staff Writer
Staff Writer
LONDON – With pressure on drug pricing on the rise, Jim Greenwood, president of the U.S. Biotechnology Innovation Organization was defending the industry's position in the U.K. yesterday, attending the Oxford University Union to debate the motion, "Big pharma prioritizes profit over patients."
